Ray of hope in Merck cost-cutting gloom: New cancer-immunotherapy data

While headlines focused on Merck's ($MRK) 8,500-job, $2.5 billion restructuring yesterday, the pharma giant quietly posted promising early-stage data on what has become its brightest pipeline prospect: the cancer immunotherapy MK-3475. Report